X
3.37
0.02 (0.60%)
| Penutupan Terdahulu | 3.35 |
| Jumlah Dagangan | 148,600 |
| Harga / Jualan (P/S) | 21.61 |
| Harga / Buku (P/B) | 2.08 |
| Julat 52 Minggu |
| Margin Keuntungan | 46.54% |
| Margin Operasi (TTM) | -32.78% |
| EPS Cair (TTM) | 2.11 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 340.14% |
| Nisbah Semasa (MRQ) | 3.70 |
| Aliran Tunai Operasi (OCF TTM) | -109.67 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -78.01 M |
| Pulangan Atas Aset (ROA TTM) | -58.61% |
| Pulangan Atas Ekuiti (ROE TTM) | 121.75% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | X4 Pharmaceuticals, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | 2.0 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | -5.0 |
| Persekitaran Makro | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | 0.13 |
|
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company’s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.43% |
| % Dimiliki oleh Institusi | 55.70% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |